FRONTIER SCIENCE | PUBLICATIONS

The HERA Trial: Adjuvant trastuzumab therapy reduces the risk of relapse across subgroups

OVERVIEW

An assessment of the magnitude of the clinical benefits of trastuzumab for subpopulations defined by nodal and steroid hormone receptor status using data from the Herceptin Adjuvant (HERA) study.

TITLE OF PUBLICATION

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

AUTHORS

Untch, M., Gelber, R.D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B. and de Azambuja, E.

PUBLICATION REFERENCE

Annals of Oncology | Volume 19 | Issue 6 | Pages 1090-1096 | June 2008

READ FULL PUBLICATION

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

ALTTO | ESMO Open

ALTTO | ESMO Open

Oct 24, 2024

Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.

read more
APHINITY | Journal of Clinical Oncology

APHINITY | Journal of Clinical Oncology

Sep 18, 2024

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

read more
OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more